Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ASENSUS SURGICAL, INC.
Report date August 22, 2024 · Filed August 22, 2024
Section 16 reporting ended · disclosed 2024-08-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 1
1 source rowRow 1 · 2024-08-22 · Disposition to issuer · Disposed 595,372 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock. F2: The reported securities include 179,084 shares of common stock issued upon the acceleration and vesting of performance-based restricted stock units. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.26 | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-22 · Disposition to issuer · Disposed 396,800 · Balance 0 F3: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.09 per underlying share of common stock only upon satisfaction of all vesting conditions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-22 · Disposition to issuer · Disposed 116,666 · Balance 0 F4: Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock. F6: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-22 · Disposition to issuer · Disposed 62,417 · Balance 0 F4: Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock. F6: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-22 · Disposition to issuer · Disposed 330,300 · Balance 0 F5: Each performance-based restricted stock unit ("PRSU") represents the right to receive one share of the Registrant's common stock. F6: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-22 · Disposition to issuer · Disposed 660,600 · Balance 0 F4: Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock. F6: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.
F2: The reported securities include 179,084 shares of common stock issued upon the acceleration and vesting of performance-based restricted stock units.
F3: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.09 per underlying share of common stock only upon satisfaction of all vesting conditions.
F4: Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock.
F5: Each performance-based restricted stock unit ("PRSU") represents the right to receive one share of the Registrant's common stock.
F6: Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions.
Zomedica Corp.
Report date August 14, 2020 · Filed August 14, 2020
Section 16 reporting ended · disclosed 2020-08-14. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Jul 2, 2021 19:14 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | Tax withholdingCommon Stock | 4,558 | $2.93 | $13,354.94 |
DisclosureSEC source: 0001209191-21-045188 · doc4.xml · nonDerivative · entry 2 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,109 Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 19:14 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045188 · doc4.xml · nonDerivative · entry 1 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Lapse of forfeiture restrictions on one third of the grant of the time-based restricted stock units ("RSUs") and on one third of the performance-based RSUs awarded on August 24, 2020. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 20:50 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantRestricted Stock Units · Derivative | 59,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008655 · doc4.xml · derivative · entry 4 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,200 Underlying: Common Stock · 59,200 shares Expires not disclosed F1 · security: Award subject to forfeiture if the Registrant's stockholders do not approve an increase in the number of shares available under the Plan at the Registrant's 2021 annual meeting of stockholders. F3 · security: Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock. F7 · derivative.exercise_date: Represents a discretionary retention bonus. Forfeiture restrictions will lapse on the RSUs on February 4, 2022, as long as the Reporting Person remains in continuous service during the vesting period. F7 · derivative.expiration_date: Represents a discretionary retention bonus. Forfeiture restrictions will lapse on the RSUs on February 4, 2022, as long as the Reporting Person remains in continuous service during the vesting period. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 20:50 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantRestricted Stock Units · Derivative | 59,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008655 · doc4.xml · derivative · entry 3 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,112 Underlying: Common Stock · 59,112 shares Expires not disclosed F1 · security: Award subject to forfeiture if the Registrant's stockholders do not approve an increase in the number of shares available under the Plan at the Registrant's 2021 annual meeting of stockholders. F5 · security: Each performance-based restricted stock unit ("PRSU") represents the right to receive one share of the Registrant's common stock. F6 · derivative.exercise_date: PRSU award with time-based vesting in three equal installments of 19,704 on each of February 4, 2022, 2023 and 2024, and performance-based vesting only if, designated corporate goals are met. F6 · derivative.expiration_date: PRSU award with time-based vesting in three equal installments of 19,704 on each of February 4, 2022, 2023 and 2024, and performance-based vesting only if, designated corporate goals are met. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 20:50 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantRestricted Stock Units · Derivative | 59,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008655 · doc4.xml · derivative · entry 2 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,112 Underlying: Common Stock · 59,112 shares Expires not disclosed F1 · security: Award subject to forfeiture if the Registrant's stockholders do not approve an increase in the number of shares available under the Plan at the Registrant's 2021 annual meeting of stockholders. F3 · security: Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock. F4 · derivative.exercise_date: Forfeiture restrictions will lapse on the RSUs in three equal installments of 19,704 on each of February 4, 2022, 2023 and 2024, as long as the Reporting Person remains in continuous service during the vesting period, subject to acceleration as set forth in the Plan and the Employment Agreement. F4 · derivative.expiration_date: Forfeiture restrictions will lapse on the RSUs in three equal installments of 19,704 on each of February 4, 2022, 2023 and 2024, as long as the Reporting Person remains in continuous service during the vesting period, subject to acceleration as set forth in the Plan and the Employment Agreement. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 20:50 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Options · Derivative | 73,078 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-21-008655 · doc4.xml · derivative · entry 1 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,078 Underlying: Common Stock · 73,078 shares Expires 2028-02-08 F1 · security: Award subject to forfeiture if the Registrant's stockholders do not approve an increase in the number of shares available under the Plan at the Registrant's 2021 annual meeting of stockholders. F2 · derivative.exercise_date: Vests one-third annually on each of February 4, 2022, 2023 and 2024, subject to acceleration as set forth in the Registrant's Amended and Restated Incentive Compensation Plan ("Plan") and the Reporting Person's Employment Agreement with the Registrant ("Employment Agreement"). Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 19:06 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048298 · doc4.xml · derivative · entry 3 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F4 · derivative.exercise_date: Represents performance-based restricted stock units with time-based vesting in three installments of 6,667, 6,667 and 6,666 on each of July 1, 2021, 2022 and 2023, and performance-based vesting only if, during the three year performance period ended August 24, 2023, the Registrant's stock price is equal to or greater than $1.00 for twenty consecutive trading days. F4 · derivative.expiration_date: Represents performance-based restricted stock units with time-based vesting in three installments of 6,667, 6,667 and 6,666 on each of July 1, 2021, 2022 and 2023, and performance-based vesting only if, during the three year performance period ended August 24, 2023, the Registrant's stock price is equal to or greater than $1.00 for twenty consecutive trading days. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 19:06 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048298 · doc4.xml · derivative · entry 2 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F3 · derivative.exercise_date: Forfeiture restrictions will lapse on the restricted stock units in three equal installments of 10,000 on each of July 1, 2021, 2022 and 2023, as long as the Reporting Person remains in continuous service during the vesting period, subject to acceleration as set forth in the Registrant's Amended and Restated Incentive Compensation Plan and the Reporting Person's Employment Agreement with the Registrant. F3 · derivative.expiration_date: Forfeiture restrictions will lapse on the restricted stock units in three equal installments of 10,000 on each of July 1, 2021, 2022 and 2023, as long as the Reporting Person remains in continuous service during the vesting period, subject to acceleration as set forth in the Registrant's Amended and Restated Incentive Compensation Plan and the Reporting Person's Employment Agreement with the Registrant. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 19:06 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001209191-20-048298 · doc4.xml · derivative · entry 1 Shameze Rampertab · CIK 0001721810 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-08-24 F1 · derivative.exercise_date: The stock options vest one-third annually on each of August 24, 2021, 2022 and 2023, as long as the Reporting Person remains in continuous service during the vesting period. Subject to acceleration of vesting in full upon consummation of a change in control of the Registrant. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 16:13 UTC | Zomedica Corp. ZOM · Entity 6884 | GrantStock Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001171843-20-001789 · ownership.xml · derivative · entry 1 Shameze Rampertab · CIK 0001721810 · Director · Interim CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Shares, without par value · 900,000 shares Expires 2025-03-13 F1 · derivative.exercise_date: The option vests in 4 equal annual installments commencing March 13, 2020. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:10 UTC | Zomedica Corp. ZOM · Entity 6884 | GrantStock Option (right to buy) · Derivative | 950,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001171843-19-000261 · ownership.xml · derivative · entry 1 Shameze Rampertab · CIK 0001721810 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Shares, without par value · 950,000 shares Expires 2021-01-10 F1 · derivative.exercise_date: The options vested upon grant. The option is currently fully vested. Read SEC document |
| March 12, 2018 Filed Mar 19, 2018 16:14 UTC | Zomedica Corp. ZOM · Entity 6884 | Exercise / conversionStock Option (right to buy) · Derivative | 176,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000905718-18-000320 · rampertab_form4mar192018.xml · derivative · entry 5 Shameze Rampertab · CIK 0001721810 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, without par value · 176,000 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested upon grant. The option is currently fully vested. Read SEC document |
| March 12, 2018 Filed Mar 19, 2018 16:14 UTC | Zomedica Corp. ZOM · Entity 6884 | Exercise / conversionCommon Shares, without par value | 176,000 | $0.20 | $35,200.00 |
DisclosureSEC source: 0000905718-18-000320 · rampertab_form4mar192018.xml · nonDerivative · entry 1 Shameze Rampertab · CIK 0001721810 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2018 Filed Jan 8, 2018 17:58 UTC | Zomedica Corp. ZOM · Entity 6884 | Exercise / conversionStock Option (right to buy) · Derivative | 124,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000905718-18-000038 · zomedica_fm4jan82018.xml · derivative · entry 5 Shameze Rampertab · CIK 0001721810 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Shares, without par value · 124,000 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested upon grant. The option is currently fully vested. Read SEC document |
| January 08, 2018 Filed Jan 8, 2018 17:58 UTC | Zomedica Corp. ZOM · Entity 6884 | Exercise / conversionCommon Shares, without par value | 124,000 | $0.20 | $24,800.00 |
DisclosureSEC source: 0000905718-18-000038 · zomedica_fm4jan82018.xml · nonDerivative · entry 1 Shameze Rampertab · CIK 0001721810 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.